![]() |
![]() |
![]() |
![]() |
1-P08 | Lower risks of sodium glucose cotransporter 2 (SGLT2) inhibitors compared to dipeptidyl peptidase-4 (DPP4) inhibitors for hepatocellular carcinoma in type 2 diabetes mellitus: A population-based study | Huang Helen | ![]() |
![]() |
|||
1-P11 | Tumour associated endothelial expression of B7-H3 predicts survival in hepatocellular carcinomas | Su Jong Yu | ![]() |
![]() |
|||
1-P10 | CT texture analysis may predict genetic profile of mass-forming intrahepatic cholangiocarcinoma | Lorenza Rimassa | ![]() |
![]() |
|||
1-P06 | A Notch-ligand producing niche drives the transition of pre-malignant biliary disease into cholangiocarcinoma | Anabel Martinez Lyons | ![]() |
![]() |
|||
1-P09 | Implication of patients experience in the liver cancer multidisciplinary approach | Gemma Iserte | ![]() |
![]() |
|||
1-P07 | Efficacy of atezolizumab in combination with bevacizumab in patients with unresectable hepatocellular carcinoma not previously treated with systemic therapy: efficacy results from the interim analysis of the Phase IIIb Italian AMETHISTA trial | Lorenza Rimassa | ![]() |
![]() |
|||
1-P05 | Macrotrabecular-Massive pattern is associated with aggressive factors, but it is not an independent predictor of tumor recurrence and overall survival in patients with hepatocellular carcinoma treated with liver resection. | Alejandro Forner | ![]() |
![]() |
|||
1-P01 | Atezolizumab in combination with bevacizumab in patients with unresectable hepatocellular carcinoma not previously treated with systemic therapy: safety results from the interim analysis of the phase IIIb Italian AMETHISTA trial | Fabio Piscaglia | ![]() |
![]() |
|||
1-P04 | Liquid biopsy protein biomarkers of cholangiocarcinoma risk, early diagnosis and survival mirroring tumor cells | Ainhoa Lapitz | ![]() |
![]() |
|||
1-P03 | Myeloid cell-derived HMGB1 protects from the development of hepatocellular carcinoma | Natalia Nieto | ![]() |
![]() |
|||
1-P02 | A novel hepatitis B virus genome integration hotspot in DEPDC5 intron-10 predicts unfavourable prognosis for hepatocellular carcinoma patients | Chau-Ting Yeh | ![]() |
![]() |
|||
2-P03 | MAP17 promotes an epithelial-mesenchymal-amoeboid transition in hepatocellular carcinoma by switching one-carbon metabolism | Claudia Gil-Pitarch | ![]() |
![]() |
|||
2-P05 | Feasibility of systemic anti-cancer therapy as an alternative to best supportive care in patients with advanced HCC and Child-Pugh B liver dysfunction | Claudia Fulgenzi | ![]() |
![]() |
|||
2-P08 | Transarterial chemoembolization and systemic treatment in patients with autoimmune liver disease-associated hepatocellular carcinoma: Outcome and safety profile | Louisa Stern | ![]() |
![]() |
|||
2-P11 | GALAD score outperforms aMAP and ALBI scores in the 5- and 10-year prediction ofhepatocellular carcinoma (HCC) development in patients with compensated advanced chronicliver disease (cACLD): a 12-year prospective study. | Valentina Baldaccini | ![]() |
![]() |
|||
2-P09 | KLF5 upregulation is a common event in cholangiocarcinoma, acting as an oncogene and constituting a bad prognostic factor | Pedro Miguel Rodrigues | ![]() |
![]() |
|||
2-P04 | Real World Data for Atezolizumab plus Bevacizumab in unresectable Hepatocellular Carcinoma: how does the adherence to the IMbrave150 trial inclusion criteria impact prognosis? | Margherita Rimini | ![]() |
![]() |
|||
2-P07 | Role of SerpinB3-PD polymorphism in the prognosis of hepatocellular carcinoma | Pietro Guerra | ![]() |
![]() |
|||
2-P01 | Regorafenib in patients with unresectable hepatocellular carcinoma in real-world practice: Final analysis of the prospective, observational REFINE study in the sorafenib-intolerant patient subgroup | Elena Dimitriou | ![]() |
![]() |
|||
2-P06 | Safety and feasibility of Atezolizumab and Bevacizumab downstaging to liver transplantation of intermediate-advanced HCC: preliminary European experience on 7 patients | Sherrie Bhoori | ![]() |
![]() |
|||
2-P02 | Mining the dark proteome to identify novel biomarkers in hepatocellular carcinoma | Doan Duy Hai Tran | ![]() |
![]() |
|||
3-P06 | Immunotherapy resistance in NASH-HCC is driven by the dysfunctional liver microenvironment of NASH | Daniel Geh | ![]() |
![]() |
|||
3-P08 | Effect of Zinc Acexamate treatment in hepatocellular carcinoma in vitro and in vivo models | Monica Higuera | ![]() |
![]() |
|||
3-P04 | Exportin-1 (XPO-1) as a novel target for natural killer cells in hepatocellular carcinoma | Salim Khakoo | ![]() |
![]() |
|||
3-P09 | Comparison between Regular Additional Endobiliary Radiofrequency Ablation and Photodynamic Therapy in Patients with Advanced Extrahepatic Cholangiocarcinoma under Systemic Chemotherapy | Christian Möhring | ![]() |
![]() |
|||
3-P03 | Targeting the E2F/MCM axis in cholangiocarcinoma halts disease progression in experimental models by rewiring lipid metabolism | Mikel Ruiz de Gauna | ![]() |
![]() |
|||
3-P07 | Identification of hepatocyte-restricted antigens, epitopes, and T cell receptors to treat recurrent hepatocellular carcinoma after liver transplantation | Yannick Rakké | ![]() |
![]() |
|||
3-P10 | Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments | Mara Persano | ![]() |
![]() |
|||
3-P11 | Incidence and risk factors of esophagogastric varices bleeding in patients with advanced Hepatocellular Carcinoma treated with Lenvatinib | Eleonora Alimenti | ![]() |
![]() |
|||
3-P05 | Interplay between genetic and immune factors in the tumor microenvironment and their prognostic value in hepatocellular carcinoma. | Filip Ambrozkiewicz | ![]() |
![]() |
|||
3-P02 | Management of varices but not anticoagulation is associated with improved outcome in patients with hepatocellular carcinoma and macrovascular tumour invasion | Lorenz Balcar | ![]() |
![]() |
|||
3-P01 | Glypican-3 targeted radiopharmaceutical therapy for hepatocellular carcinoma: Preclinical characterization of a novel peptide binder | Gary Li | ![]() |
![]() |
|||
4-P11 | Time-trends in cholangiocarcinoma incidence - a Danish nationwide cohort study | Morten Daniel Jensen | ![]() |
![]() |
|||
4-P04 | Artificial intelligence and deep learning models used for the classification and navigation of liver ultrasound protocols for patients with hepatocellular carcinoma | Joseph Klepich | ![]() |
![]() |
|||
4-P01 | Barriers to hepatocellular carcinoma screening at a single Veterans Affairs center: a quality improvement initiative | Maureen Onweni-Eze | ![]() |
![]() |
|||
4-P03 | The ALBI grade refines prognostic prediction in advanced hepatocellular cancer and enables risk stratification for bleeding events following atezolizumab plus bevacizumab. | Antonio DAlessio | ![]() |
![]() |
|||
4-P02 | Value based Healthcare: Patient perception of the liver cancer Advanced Practice Nurse care at the Barcelona Clinic Liver Cancer | Neus Llarch | ![]() |
![]() |
|||
4-P06 | Peripheral immune markers can detect hepatocellular carcinoma in blood in a Latin American cohort | Boonstra Andre | ![]() |
![]() |
|||
4-P05 | Cryptogenic non-cirrhotic HCC: clinical, prognostic and immunologic aspects of an emerging HCC etiology | Boonstra Andre | ![]() |
![]() |
|||
4-P09 | Dissecting the tumor heterogeneity and tumor microenvironment in intrahepatic cholangiocarcinoma using spatial transcriptomics | Mareike Polenkowski | ![]() |
![]() |
|||
4-P10 | An innovative human-derived Cholangiocarcinoma-on-chip as a platform for targeted therapy | Michela Anna Polidoro | ![]() |
![]() |
|||
4-P08 | The role of Aurora kinase A in hepatocellular carcinoma: possible regulation of Programmed death-ligand 1 | Luca Grisetti | ![]() |
![]() |
|||
4-P07 | Fibroblast growth factor 21 delays hepatocellular carcinoma development and is critical for liver regeneration in a murine model of moderate and severe liver injury | Hanna Luisa Martin | ![]() |
![]() |
|||
5-P01 | Predicting cardiovascular risk in patients with hepatocellular carcinoma receiving anti-angiogenic drugs: lessons from sorafenib | Bernardo Stefanini | ![]() |
![]() |
|||
5-P11 | Therapeutic potential of targeting protein hyper-SUMOylation in cholangiocarcinoma | Paula Olaizola Rebe | ![]() |
![]() |
|||
5-P07 | The earliest integration of hepatitis B virus into hepatocyte genome: sites, mechanism and role in HCC oncogenesis | Thomas I. Michalak | ![]() |
![]() |
|||
5-P10 | Targeting epigenetics in preclinical models of Hepatocellular Carcinoma for translational therapy. | Anastasia Georgakopoulou | ![]() |
![]() |
|||
5-P08 | A novel hepatocellular cancer patient derived organoid xenograft model to investigate impact of liver regeneration on tumor growth | Fabian Haak | ![]() |
![]() |
|||
5-P03 | Centrosome amplification is attributed to glutamine metabolism in the developments of liver fibrosis and liver tumors | Caroline Oi-Ling Yu | ![]() |
![]() |
|||
5-P06 | Impact of the covid-19 pandemic on the treatment of resectable liver neoplasias: a cross-sectional study from Brazil | Laynara Vitória Da Silva Vieira | ![]() |
![]() |
|||
5-P05 | ASSOCIATION OF TP53 WITH DEFECTIVE LONG CHAIN 3-HYDROXY ACYL-CoA DEHYDROGENASE INDUCED NON-CIRRHOTIC HEPATOCELLULAR CARCINOMA | Tripti Khare | ![]() |
![]() |
|||
5-P09 | Prognostic impact of metastatic site in patients receiving first-line sorafenib therapy for advanced hepatocellular carcinoma | Luca Ielasi | ![]() |
![]() |
|||
6-P05 | Preferential effects of PARP-1 inhibition in KRAS-mutated intrahepatic cholangiocarcinoma is mediated by CHK1 kinase | Darko Castven | ![]() |
![]() |
|||
6-P06 | Gamma-aminobutyric acid B2 receptor as a potential therapeutic target for cholangiocarcinoma with diabetes mellitus | Charupong Saengboonmee | ![]() |
![]() |
|||
6-P02 | Novel platinum-based chemotherapeutic agents halt cholangiocarcinoma progression through the induction of inter-strand DNA breaks, preventing DNA repair mechanisms | Irene Olaizola Rebe | ![]() |
![]() |
|||
6-P07 | KDM2A histone demethylase ablation restores immunogenicity in liver cancer | Elisa Morganti | ![]() |
![]() |
|||
6-P03 | Proteomic profile matching predicts treatment response in advanced hepatocellular carcinoma for precision medecine | Frederic SALTEL | ![]() |
![]() |
|||
6-P10 | Metabolic rewiring by increased mitochondrial respiration drives immunosuppression in liver cancer | Naroa Goikoetxea Usandizaga | ![]() |
![]() |
|||
6-P01 | Survival outcomes from Atezolizumab plus Bevacizumab versus Lenvatinib versus Sorafenib in Child Pugh B unresectable hepatocellular carcinoma patients. | Margherita Rimini | ![]() |
![]() |
|||
6-P08 | A prognostic nomogram of CDKs/CDKLs-related genes for hepatocellular carcinoma | Ningning Zhang | ![]() |
![]() |
|||
6-P04 | Scavenger receptor MARCO is associated with an immunosuppressive microenvironment and tumor progression in intrahepatic cholangiocarcinoma | Aloña Agirre Lizaso | ![]() |
![]() |
|||
7-P02 | Modelling hepatocellular carcinoma in precision-cut liver slices for therapeutic screening and as a precision medicine tool | Amy Collins | ![]() |
![]() |
|||
7-P03 | Identification and experimental validation of druggable epigenetic targets in hepatoblastoma. | Claveria-Cabello Alex | ![]() |
![]() |
|||
7-P10 | T cell and myeloid cell interactions differ in tumour and non-tumour regions in hepatocellular carcinoma | Cositha Santhakumar | ![]() |
![]() |
|||
7-P08 | Baveno VI and VII criteria are not suitable for screening of large size esophageal varices and clinically significant portal hypertension in patients with HCC | Manon Allaire | ![]() |
![]() |
|||
7-P07 | Metformin and statin reduce the risk of hepatocellular carcinoma among chronic hepatitis C patients failed to antiviral therapy | Pei-Chien Tsai | ![]() |
![]() |
|||
7-P06 | Pediatric liver cancer: Hepatoblastoma and Neddylation post-translational modification | Leidy Estefanía Zapata-Pavas | ![]() |
![]() |
|||
7-P05 | Developing image-guided precision radiotherapy in preclinical liver cancer models | Stephanie May | ![]() |
![]() |
|||
7-P09 | Trial in progress: An open-label, multicenter study investigating RP3 oncolytic immunotherapy in combination with first- or second-line systemic atezolizumab and bevacizumab in locally advanced unresectable or metastatic hepatocellular carcinoma | Jane Kovalevich | ![]() |
![]() |
|||
7-P11 | miRNome profiling analysis reveals novel hepatocellular carcinoma diagnostic, prognostic and treatment-related candidate biomarkers: post-hoc analysis of SORAMIC trail | Egidijus Morkunas | ![]() |
![]() |
|||
7-P04 | Portal-hypertension parameters are associated with survival and ascites occurrence in patients with hepatocellular carcinoma treated by external radiotherapy | Héloïse Giudicelli | ![]() |
![]() |
|||
7-P01 | Silencing CNNM4 in cholangiocarcinoma inhibits tumoral progression by means of non-canonical ferroptosis | Maria Mercado-Gómez | ![]() |
![]() |
|||
8-P03 | Spheroids derived from aggressive hepatocellular carcinoma (HCC) or intrahepatic cholangiocarcinoma (iCCA) share similar behaviour after proangiogenic stimulation | Adriana Romanzi | ![]() |
![]() |
|||
8-P11 | secondary surveillance following curative treatment of hepatocellular carcinoma: a systematic review | Shauntelle Quammie | ![]() |
![]() |
|||
8-P01 | MiR-494 induces metabolic reprogramming through G6pc targeting and modulates sorafenib response in hepatocellular carcinoma | Ilaria Leoni | ![]() |
![]() |
|||
8-P09 | Oncogenic role of the Hepatitis B Virus surface antigen during hepatocarcinogenesis | Agustiningsih Agustiningsih | ![]() |
![]() |
|||
8-P08 | Impact of sarcopenia on survival of patients with hepatocellular carcinoma treated with sorafenib | Lorenzo Lani | ![]() |
![]() |
|||
8-P07 | The Differences in Profiles of Intratumoral Microbiota in Cholangiocarcinoma and Hepatocellular Carcinoma are Observed | Thanika Ketpueak | ![]() |
![]() |
|||
8-P06 | Clinical and biologic qualification of the ABRS gene signature, a putative biomarker of benefit to atezolizumab and bevacizumab in advanced hepatocellular cancer | Cian Murphy | ![]() |
![]() |
|||
8-P04 | Incidence rates, trends, and survival for etiology-specific hepatocellular carcinoma and cholangiocarcinoma in the Unites States. | Paulo Pinheiro | ![]() |
![]() |
|||
8-P05 | Cytokine levels and circulating DNA profiling in plasma as biomarkers of response to immunotherapy in hepatocellular carcinoma | Elena Vargas Accarino | ![]() |
![]() |
|||
8-P02 | Phenotypic characteristics of primary cholangiocarcinoma in a large French cohort of patients with viral chronic liver disease followed-up before and after viral eradication: an ANRS study | Alina Pascale | ![]() |
![]() |
|||
8-P10 | Collagen proportionate area (CPA) measurement of liver parenchyma and hepatocellular carcinoma (HCC) can predict HCC recurrence after liver resection | Federico Ravaioli | ![]() |
![]() |
|||
9-P10 | Uncovering epigenetic essentialities of intrahepatic cholangiocarcinoma | Juan Lafuente-Barquero | ![]() |
![]() |
|||
9-P07 | Hepatocellular Carcinoma in HIV-infected patients: clinical presentation and outcomes | Eleonora Alimenti | ![]() |
![]() |
|||
9-P06 | Correlation of single nucleotide polymorphisms and hepatocellular carcinoma in a Latin American population | Boonstra Andre | ![]() |
![]() |
|||
9-P08 | Stabilization of O-GlcNAcylation increases Enhancer of Zeste Homolog 2 (Ezh2) direct targets in hepatocellular carcinoma | Margot Thirion | ![]() |
![]() |
|||
9-P02 | chimeric antigen receptor-engineered memory-like natural killer cells: a novel therapy for hepatocellular carcinoma | Rosalba Biondo | ![]() |
![]() |
|||
9-P11 | Landmark analysis of the risk of recurrence after resection or ablation for hepatocellular carcinoma: a nationwide study | Frederik Kraglund | ![]() |
![]() |
|||
9-P01 | Developing new therapies for primary liver cancer with precision bio-printed patient-derived organoids | Benjamin Dwyer | ![]() |
![]() |
|||
9-P09 | Impact of PNPLA3 rs738409 polymorphism on the development of hepatocellular carcinoma in female patients with non-alcoholic fatty liver disease and severe liver fibrosis | Nuria Pérez Diaz del Campo | ![]() |
![]() |
|||
9-P05 | Evaluation of ESPL1 level in peripheral blood of patients with HBV infection for early warning of HCC occurrence and recurrence | Hengkai Liang | ![]() |
![]() |
|||
10-P04 | Predictive performance of HCC risk scores in chronic hepatitis C patients with advanced fibrosis after achieving SVR: Real-world experience from a tertiary UK centre | Riham Soliman | ![]() |
![]() |
|||
10-P10 | Adverse events related to atezolizumab-bevacizumab is comparable among CTP-A and B and more safer than TKIs for Hepatocellular carcinoma | Anand Kulkarni | ![]() |
![]() |
|||
10-P05 | Correction for length bias reduces the mortality benefit from Hepatocellular Carcinoma surveillance | Callum Robins | ![]() |
![]() |
|||
10-P09 | Novel approaches to improve immunotherapy for NASH-induced HCC | Chaofan Fan | ![]() |
![]() |
|||
10-P06 | Role of Etiology in Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Counterfactual Event-Based Mediation Analysis | Rodolfo Sacco | ![]() |
![]() |
|||
10-P11 | identifying and analyzing metabolic reprogramming in hcc. | Asha Balakrishnan | ![]() |
![]() |
|||
10-P02 | miR-21-5p promotes NASH-related hepatocarcinogenesis | André L. Simão | ![]() |
![]() |
|||
10-P01 | The tumor milieu of Intrahepatic Cholangiocarcinoma: dissecting the phenotypical and molecular properties of B lymphocytes in affected patients | Giulia Milardi | ![]() |
![]() |
|||
10-P07 | Hepatocellular carcinoma (HCC) management in a tertiary HPB centre - lessons from the southeast coast of the UK | Darren DSouza | ![]() |
![]() |
|||
10-P03 | RIPK3 impacts tumor burden and liver immunophenotype in toxic/dietary models of hepatocellular carcinoma | André Cardador | ![]() |
![]() |
|||
11-P02 | The importance of contrast enhanced ultrasonography and elastography as predictors for hepatocellular carcinoma recurrence following treatment with percutaneous microwave ablation or transarterial chemoembolization | Razvan Rababoc | ![]() |
![]() |
|||
11-P07 | Regorafenib in patients with unresectable hepatocellular carcinoma in real-world practice in the European Union: Final analysis of the prospective, observational REFINE study | Elena Dimitriou | ![]() |
![]() |
|||
11-P06 | Prognostic performance of Toronto HCC risk index and the alpha-fetoprotein rate in patients with Hepatocellular carcinoma | Nouha Trad | ![]() |
![]() |
|||
11-P01 | Tolerability of first line systemic therapy in elderly patients with advanced hepatocellular carcinoma | Giulia Francesca Manfredi | ![]() |
![]() |
|||
11-P10 | Alpha-Fetoprotein Response Patterns after Y-90 Radioembolization for Intermediate-to-Advanced Hepatocellular Carcinoma Predict Disease Progression and Survival | Justin Tse | ![]() |
![]() |
|||
11-P05 | The epidemiology of hepatocellular carcinoma has changed in our region ... But, what has really changed ? | Edeline Kaze | ![]() |
![]() |
|||
11-P08 | A transcriptomic signature of Intrahepatic Cholangiocellular Carcinoma with very early recurrence: Identifying patients at risk | Fabian Haak | ![]() |
![]() |
|||
11-P09 | Atezolizumab/Bevacizumab combination therapy seems to benefit mainly BCLC-C cirrhotic patients with hepatocellular carcinoma who migrate to this stage after disease recurrence following resection or radiofrequency ablation | Spyridon Pantzios | ![]() |
![]() |
|||
11-P04 | Hypofractionated Carbon Ion Radiation in patients with primary liver cancer | Paula Hoffmeister-Wittmann | ![]() |
![]() |
|||
11-P03 | Robotic and laparoscopic surgery versus open surgery for perihilar cholangiocarcinoma: systematic review and meta-analysis | Laynara Vitória Da Silva Vieira | ![]() |
![]() |
|||
12-P07 | Survival in people living with HIV with or without recurrence of hepatocellular carcinoma after invasive therapy | Costanza Bertoni | ![]() |
![]() |
|||
12-P09 | The role of thyroid hormone signalling in liver carcinogenesis: a proof of knowledge | Valentina Cossiga | ![]() |
![]() |
|||
12-P01 | Evaluation of hepatocellular carcinoma and mortality in Budd-Chiari syndrome | Zülal Istemihan | ![]() |
![]() |
|||
12-P02 | Updated survival outcomes with ivosidenib in patients with previously treated IDH1-mutated intrahepatic-cholangiocarcinoma: an Italian real-world experience. | Margherita Rimini | ![]() |
![]() |
|||
12-P05 | ??????????? ???? ??????????????? ??????????? ????????????????? ????????? | Alexander Fedusenko | ![]() |
![]() |
|||
12-P10 | Expression of MIR-199-5p in chronic viral hepatitis and hepatocellular carcinoma | Elizaveta Joldasova | ![]() |
![]() |
|||
12-P03 | Use of cytokine TGF 1 in DETECTION of Hepatocellular carcinoma in patients with chronic liver disease | Amila Mehmedovic | ![]() |
![]() |
|||
12-P04 | The potential of combined treatments between Src tyrosine kinase inhibitors and sorafenib in heterogeneous liver cancer cells | Loraine Kay Cabral | ![]() |
![]() |
|||
12-P08 | Temporal trends in Hepatocellular carcinoma in Pakistan | Aimun Raees | ![]() |
![]() |
|||
12-P06 | The association of glucagon-like peptide-1 receptor and poor prognosis of Northeastern Thai patients with cholangiocarcinoma | Ronnakrit Trakoonsenathong | ![]() |
![]() |
|||
12-P11 | Reduced expression of YAP is associated with transition of pre-invasive to invasive state in an organoid-derived model of cholangiocarcinoma | Fatima Manzano-Nuñez | ![]() |
![]() |
|||
13-P05 | Inhibiting methionine aminopeptidase 2 suppressed VEGFA-mediated angiogenesis by enhancing phosphorylation of eIF2a | Yongtao Wang | ![]() |
![]() |
|||
13-P08 | The gene expressions and bioinformatics analysis of miR-146b-5p and miR-4510 in Hepatocellular Carcinoma | Duygu BIRCAN KADIOGLU | ![]() |
![]() |
|||
13-P10 | Poor sorafenib response in hepatocellular carcinoma is mediated by hypoxia-related 14-3-3 scaffolding proteins and induces shift in immune micromilieu | Jovana Castven | ![]() |
![]() |
|||
13-P02 | Glycosylated 4-methylumbelliferone reduces the expressions of cancer stem cells in hepatocellular carcinoma | Caecilia Sukowati | ![]() |
![]() |
|||
13-P09 | TARDBP Is a Prognostic Biomarker and Correlates With Immune Infiltrates in Liver hepatocellular carcinoma | Ningning Zhang | ![]() |
![]() |
|||
13-P04 | Investigation of novel hepatoblastoma chemosensitizers based on the inhibition of ABC pumps-mediated drug efflux | Rocio IR Macias | ![]() |
![]() |
|||
13-P06 | Synergistic Anticancer Effect of Immunotherapy and PI3K? Inhibition Combination Therapy in Liver Cancer | Sue Hyuck | ![]() |
![]() |
|||
13-P01 | PRAME is a target of Gas6/Axl signaling in hepatocellular carcinoma | Wolfgang Mikulits | ![]() |
![]() |
|||
13-P07 | It takes a team for HCC: improvement of outcome with the multidisciplinary ambulatory for systemic therapy | Dalbeni Andrea | ![]() |
![]() |
|||
13-P03 | Therapeutic potential of engineered oncolytic virus 3020-VV13 in a pre-clinical model of hepatocellular carcinoma | Hyeree Kim | ![]() |
![]() |
|||
14-P06 | The role of radiomics in the diagnostic and therapeutic path of hepatocellular carcinoma treated with trans arterial radio embolization | Flavia Federici | ![]() |
![]() |
|||
14-P05 | The role of radiomics in diagnosis and therapeutic path of hepatocellular carcinoma treated with transarterial chemoembolization | Paola Ferrari | ![]() |
![]() |
|||
14-P10 | Oncostatin M promotes a pro-tumorigenic inflammatory response in NASH-related HCC | Beatrice Foglia | ![]() |
![]() |
|||
14-P01 | Validation of the CRAFITY score in patients with hepatocellular carcinoma treated with atezolizumab and bevacizumab | Bernhard Scheiner | ![]() |
![]() |
|||
14-P09 | Effects of Rifaximin on Epigenetic and Autophagy Markers in an Experimental Model of Hepatocellular Carcinoma Secondary to Non-alcoholic Fatty Liver Disease. | Matheus Michalczuk | ![]() |
![]() |
|||
14-P02 | Cellular interrogation of changes to anti-tumour immunity in Hepatocellular Carcinoma following treatment with combined atezolizumab and bevacizumab using human Precision-Cut Tumour Slices | Ravi Jagatia | ![]() |
![]() |
|||
14-P11 | Carcinogenesis risk factors in cirrhotic patients with dysplastic nodules | Elena Laura Iliescu | ![]() |
![]() |
|||
14-P07 | Hepatocellular Carcinoma cell lines growth inhibition by liver-derived mensenchymal stem cells in direct 3D co-culture | Grégory de Bodt | ![]() |
![]() |
|||
14-P03 | Clinical characteristics, treatments and outcomes in patients diagnosed with hepatocellular carcinoma (HCC) receiving locoregional treatment in England | Sophia Le Mare | ![]() |
![]() |
|||
15-P08 | Tolerance and efficacy of the early switch towards atezolizumab bevacizumab after failure of ive internal radiation therapy for hepatocellular carcinoma | Yasmina Ben Merabet | ![]() |
![]() |
|||
15-P01 | Inhibiting endoplasmic reticulum stress enhances the effect of doxorubicin by affecting lipid metabolism in hepatocellular carcinoma | MARIA KOPSIDA | ![]() |
![]() |
|||
15-P06 | Fascin-1 as a druggable target in agressive hepatoblastoma | Lydia DIF | ![]() |
![]() |
|||
15-P10 | Long-term survival in patients with unresectable liver cancer treated with lenvatinib | Maria Teresa Ferrer Rios | ![]() |
![]() |
|||
15-P02 | Interim analysis of the ACTION trial: Cabozantinib for hepatocellular carcinoma patients who discontinued first line treatment different to sorafenib or due to sorafenib intolerance | Marco Sanduzzi Zamparelli | ![]() |
![]() |
|||
15-P05 | Hepatocellular carcinoma incidence and risk stratification in patients with non-alcoholic fatty liver disease on long-term follow-up | Marta Guariglia | ![]() |
![]() |
|||
15-P07 | NMS-01940153E, an MPS1 inhibitor with anti-tumor activity in relapsed or refractory unresectable hepatocellular carcinoma | Domenico Roberti | ![]() |
![]() |
|||
15-P11 | A prospective study for validation of General Evaluation Score for hepatocellular carcinoma risk stratification in chronic hepatitis C patients | Gamal Shiha | ![]() |
![]() |
|||
16-P11 | Influence of the SUSTAINED VIRAL RESPONSE (SVR) in patients with cirrhosis due to HEPATITIS C VIRUS (HCV) and diagnosis of HEPATOCELLULAR CARCINOMA (HCC) | Maria Varela | ![]() |
![]() |
|||
16-P04 | Serum HCC biomarkers AFP, PIVKAII and GPC-3 correlate differently with the HCC characteristics and clinic-pathologic features. | Francesco Damone | ![]() |
![]() |
|||
16-P07 | Establishment and characterization of a patient derived xenograft model of cholangiocarcinoma | Denise Schlösser | ![]() |
![]() |
|||
16-P06 | Glycogen as metabolic fuel for tumor development in glycogen storage disease type III | Valle Montalvo Romeral | ![]() |
![]() |
|||
16-P05 | Prognostic role of thyroid volume reduction in patients treated with lenvatinib for advanced hepatocellular carcinoma | Luca Ielasi | ![]() |
![]() |
|||
16-P08 | INTERLEUKIN-6: a new marker of advanced-sarcopenic HCC cirrhotic patients | Leonardo Antonio Natola | ![]() |
![]() |
|||
16-P01 | Validation of serum biomarker panels for early HCC detection: Results from a large prospective Latin American multicenter study | Boonstra Andre | ![]() |
![]() |
|||
16-P09 | Liposomal doxorubicin targeted with atezolizumab as a novel strategy to cure HCC: preclinical in vitro and in vivo studies | Sara De Martin | ![]() |
![]() |
|||
17-P10 | Peritumoral portal enhancement during transarterial chemoembolization a potential prognostic factor for patients with hepatocellular carcinoma | Sofi Sennefelt Nyman | ![]() |
![]() |
|||
17-P06 | Fatty acid synthase promotes the malignant features of cholangiocarcinoma cells and predicts survival in patients | Giulia Lori | ![]() |
![]() |
|||
17-P05 | Liver function is a predictor of survival in patients with hepatocellular carcinoma in best supportive care | Fabio Marra | ![]() |
![]() |
|||
17-P01 | Poor compliance in the surveillance for Hepatocellular carcinoma (HCC) in a real world setting. | Maria Melanie Deutsch | ![]() |
![]() |
|||
17-P07 | Rising admissions and treatments for hepatocellular carcinoma in Irish hospitals (2009-2020) | William Shanahan | ![]() |
![]() |
|||
17-P03 | Mangiferin & Resveratrol; novel nutraceuticals regulating CD8 cell cytotoxicity and pivotal immunoregulatory pathways in hepatocellular carcinoma | Yousra Eldiwany | ![]() |
![]() |
|||
17-P09 | Insulin-like growth factor-binding proteins 2 and 3 and the occurrence, characteristics, and outcome of hepatitis C-related hepatocellular carcinoma: A case-control study | hend ibrahim shousha | ![]() |
![]() |
|||
17-P04 | Multidisciplinary approach to Hepatocellular Carcinoma management in a low-income country | Aimun Raees | ![]() |
![]() |
|||
17-P08 | Impact of surveillance strategies for hepatocellular carcinoma on patients with chronic liver diseases | Timofte Oana | ![]() |
![]() |
|||
17-P02 | Cystic Fibrosis may be an exclusion criteria for LI-RADS | Chuhadry Khuram Shahzad | ![]() |
![]() |
|||
17-P11 | Inflammation and immune-based prognostic scores as prognostic biomarkers for HCC treatment: A single-center study in the last decade | Merve Guzel Dirim | ![]() |
![]() |
|||
18-P06 | Predictors of extrahepatic recurrence after transarterial chemoembolization as first-line therapy for hepatocellular carcinoma | Elisa Pinto | ![]() |
![]() |
|||
18-P09 | Immune checkpoint inhibitor treatment has the potential to stabilize liver function in patients with hepatocellular carcinoma | Katharina Pomej | ![]() |
![]() |
|||
18-P02 | Influence of hepatocellular carcinoma surveillance programs on cirrhotic patients survival: A real life study | Félix Fernández García | ![]() |
![]() |
|||
18-P03 | Early diagnosis of hepatocellular carcinoma at the level of an infectious diseases hospital | Krestina Brigida | ![]() |
![]() |
|||
18-P04 | Serum protein glycomics in treatment-naive HCC patients are strongly associated to two-year overall survival and HCC relapse | Nicky Somers | ![]() |
![]() |
|||
18-P01 | Prognostic performance of Toronto HCC risk index in patients with Hepatocellular carcinoma | Nouha Trad | ![]() |
![]() |
|||
18-P05 | What changed in hepatocellular carcinoma presentation in the last eleven years? Comparison of two sequential time series from a tertiary hospital | Ana Craciun | ![]() |
![]() |
|||
18-P08 | Immunomonitoring of hepatocellular carcinoma patients undergoing liver transplantation after treatment with Bevacizumab and Atezolizumab | Sherrie Bhoori | ![]() |
![]() |
|||
18-P07 | Programmable DNA hydrogel assisting microcrystal formulations for sustained locoregional drug delivery in residual tumor foci | Hao Feng | ![]() |
![]() |
|||
18-P10 | Gender differences in patients with hepatocellular carcinoma | Agata Ladic | ![]() |
![]() |
|||
19-P07 | Varices and thrombocytopenia are predictors of survival outcome after liver resection for hepatocellular carcinoma (HCC): a twenty-year retrospective study | Samir Tariq | ![]() |
![]() |
|||
19-P01 | Ablation of large HCC using a new mini-invasive RFA device with 4 very thincool-tip needles | Luciano Tarantino | ![]() |
![]() |
|||
19-P04 | Efficacy of LENVATINIB in intermediate stage and advanced HEPATOCELLULAR CARCINOMA: results of MONOTHERAPY and COMBINATION with LOCOREGIONAL TREATMENT | Margherita Spigaroli | ![]() |
![]() |
|||
19-P09 | Comparison between hepatocellular carcinoma in alcohol related disease versus other etiologies - are they the same or not quite yet? A retrospective analysis. | Jessica Chaves | ![]() |
![]() |
|||
19-P08 | Fib4 can help cost effective HCC screening populations in Child Pugh A cirrhosis | Paul Armstrong | ![]() |
![]() |
|||
19-P03 | In vivo characterization of the impact of distinct p53 mutations in hepatocellular carcinoma | Marine Bernardet | ![]() |
![]() |
|||
19-P02 | Liver transplantation for HCC beyond Milan criteria after down-staging with stereotactic radiotherapy or transarterial radioembolization | Alberto Calleri | ![]() |
![]() |
|||
19-P11 | Epidemiology of hepatocelullar carcinoma in transylvania | Elena Cristina Rezi | ![]() |
![]() |
|||
20-P05 | Disparities in access to timely diagnosis and treatment for hepatocellular carcinoma - need for standardisation across cancer types | Niamh Mehigan | ![]() |
![]() |
|||
20-P10 | Assesment Of GALAD Score As Diagnostic And Prognostic Factor Of Denovo Hepatocellular Carcinoma Post Treatment With Direct Acting Antiviral Agents | hend ibrahim shousha | ![]() |
![]() |
|||
20-P08 | TKI treatments for HCC before liver transplantation: a collaborative European study. | Chiara Mazzarelli | ![]() |
![]() |
|||
20-P09 | PNPLA3 rs738409 CG polymorphism impact on HCV-Related HCC development in a Brazilian population: preliminary results | Claudia Maccali | ![]() |
![]() |
|||
20-P04 | Is ALBI score alone a good predictor for outcome in patients treated with radioembolization for hepatocellular carcinoma? | maria alessia papassifachis | ![]() |
![]() |
|||
21-P3 | Early detection of hepatocellular carcinoma via no end-repair enzymatic methylation sequencing of cell-free DNA and pre-trained neural network | Yongkun Ji | ![]() |
![]() |
20-22 April, Estoril
![]() |
Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. ![]() To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress. ![]() |
![]() |
||
![]() |
|